PT Sariguna Primatirta (CLEO) Stock: Pros and Cons for Investors
Published: August 8, 2026
Last Updated: August 8, 2026
Financial data and analysis reviewed as of August 8, 2026.
 |
| PT Sariguna Primatirta (CLEO) |
Worldreview1989 - PT Sariguna Primatirta Tbk (IDX: CLEO) is an Indonesian consumer-staples company best known for its Cleo bottled drinking water brand. For U.S. investors, CLEO offers an interesting way to gain exposure to Indonesia’s growing packaged-water and consumer sector, but the stock also comes with risks that are very different from those of PT Sariguna Primatirta (CLEO) Stock: Pros and Cons for Investors a typical U.S.-listed consumer company.
CLEO is listed on the Indonesia Stock Exchange (IDX) rather than the NYSE or Nasdaq. Investors outside Indonesia therefore need to consider currency risk, market liquidity, Indonesian regulations, and the mechanics of investing in an emerging-market stock.
The bigger question for 2026 is whether CLEO’s expansion strategy can convert strong revenue growth into sustainable earnings growth while maintaining attractive returns on capital.
What Is PT Sariguna Primatirta?
 |
| PT Sariguna Primatirta |
PT Sariguna Primatirta Tbk is an Indonesian beverage company operating under the Tanobel Food group. Its flagship brand is Cleo, a packaged drinking-water brand launched in Indonesia in the early 2000s.
The company also produces other beverage-related products and has built an extensive production and distribution network across Indonesia.
CLEO's business is particularly interesting because bottled water is a consumer-staples category. Demand tends to be less economically sensitive than discretionary products because drinking water is a basic necessity.
The company has also invested heavily in production capacity and distribution infrastructure, giving it an opportunity to benefit from Indonesia's large population and rising demand for packaged drinking water.
According to the company's investor-relations materials, financial statements for 2025 and 2026 are publicly available through its website.
CLEO Stock: The Investment Case in One Table
| Factor | 2026 Assessment |
|---|---|
| Business quality | Positive |
| Revenue growth | Positive |
| Profit growth | Recovering |
| Gross margin | Strong |
| Balance sheet | Reasonably healthy |
| Debt risk | Moderate |
| Dividend | Low yield, growth-oriented |
| Valuation | Not cheap |
| Expansion potential | High |
| Currency risk for U.S. investors | High |
| Liquidity risk | Higher than U.S. large caps |
| Overall outlook | Moderately Bullish, valuation-sensitive |
The main attraction is not the dividend. The investment thesis is primarily based on long-term earnings growth, market expansion, production capacity, and distribution scale.
CLEO Financial Performance
The company's 2025 results provide an important starting point for evaluating the stock.
CLEO generated approximately IDR 2.83 trillion in revenue in 2025, compared with IDR 2.70 trillion in 2024. That represents revenue growth of roughly 4.8%.
However, profitability was weaker.
Net income declined from approximately IDR 465.2 billion in 2024 to IDR 381.8 billion in 2025, a decline of roughly 17.9%.
FY2025 Financial Snapshot
| Metric | FY2024 | FY2025 | Change |
|---|---|---|---|
| Revenue | IDR 2.70T | IDR 2.83T | +4.8% |
| Gross Profit | IDR 1.57T | IDR 1.58T | +0.6% |
| EBITDA | IDR 868.8B | IDR 807.0B | -7.1% |
| Net Income | IDR 465.2B | IDR 381.8B | -17.9% |
| Gross Margin | ~58.3% | 55.9% | Lower |
| EBITDA Margin | ~32.2% | 28.6% | Lower |
| Net Margin | ~17.2% | 13.5% | Lower |
The most important issue is therefore margin compression.
Revenue increased, but the company did not convert that growth into higher earnings.
For investors, this distinction matters.
A company can grow sales rapidly while creating little shareholder value if operating costs and capital requirements rise faster than revenue.
Q1 2026 Shows Signs of Recovery
The encouraging development is that CLEO's financial performance improved during the first quarter of 2026.
Revenue reached approximately IDR 774.4 billion, up 15.8% year over year from IDR 668.9 billion.
Gross profit increased 11.1% to approximately IDR 438.6 billion, while EBITDA increased 8.1% to IDR 234.1 billion.
Net income reached approximately IDR 119.8 billion, compared with IDR 116.5 billion in Q1 2025.
Q1 2026 Financial Snapshot
| Metric | Q1 2025 | Q1 2026 | YoY |
|---|---|---|---|
| Revenue | IDR 668.9B | IDR 774.4B | +15.8% |
| Gross Profit | IDR 394.9B | IDR 438.6B | +11.1% |
| EBITDA | IDR 216.6B | IDR 234.1B | +8.1% |
| Net Income | IDR 116.5B | IDR 119.8B | +2.8% |
| Gross Margin | ~59.0% | 56.6% | Lower |
| EBITDA Margin | ~32.4% | 30.2% | Lower |
| Net Margin | ~17.4% | 15.5% | Lower |
The numbers show an important trend.
Revenue growth has accelerated, but profit growth remains much slower than sales growth.
That means investors should watch whether CLEO can improve operating leverage as its new facilities become productive.
Why CLEO's Margins Matter
One of CLEO's strongest characteristics is its high gross margin.
A gross margin above 50% gives the company a significant cushion against increases in packaging, logistics, labor, and other operating costs.
However, the decline in gross margin from 2024 to 2025 and again in Q1 2026 deserves attention.
For a bottled-water company, costs can be affected by:
PET and plastic prices
Energy costs
Transportation
Distribution expenses
Labor
Packaging materials
Advertising and marketing
New factory start-up costs
The company therefore needs sufficient pricing power and scale to maintain profitability.
The most important question for 2026–2027 is whether additional manufacturing capacity can increase volume faster than operating expenses.
Balance Sheet Analysis
CLEO ended 2025 with approximately:
Total assets: IDR 3.02 trillion
Total equity: IDR 2.31 trillion
Short-term debt: IDR 326.3 billion
Long-term debt: IDR 380.4 billion
Debt-to-equity: approximately 0.31x
EBITDA: approximately IDR 807 billion
These figures suggest that CLEO does not currently have an excessively leveraged balance sheet.
Its debt burden is relatively manageable compared with its EBITDA generation.
This is an important positive because CLEO is entering a capital-intensive expansion period.
However, Q1 2026 showed higher short-term debt of approximately IDR 455.6 billion, while long-term debt was approximately IDR 370.8 billion. Total equity increased to about IDR 2.43 trillion.
This indicates that investors should monitor leverage as the company funds new factories and other capital expenditures.
CLEO's 2026 Expansion Strategy
Expansion is one of the most important parts of the CLEO investment thesis.
The company plans to build or operate three additional production facilities:
| Location | Expected Timing |
|---|---|
| Palu, Central Sulawesi | Q3 2026 |
| Pontianak, West Kalimantan | Q4 2026 |
| Pekanbaru, Riau | Q4 2026 |
The company is reportedly allocating approximately IDR 700 billion in capital expenditure for 2026.
The strategic logic is straightforward.
Producing water closer to customers can reduce transportation distances and distribution costs while improving regional availability.
This is particularly important in Indonesia because the country consists of thousands of islands.
A production facility located closer to demand can provide an advantage that is difficult to replicate simply through national marketing.
The expansion strategy is expected to strengthen CLEO's presence outside Java and support its long-term growth ambitions.
Pros of Investing in CLEO Stock
1. Exposure to Indonesia's Consumer Market
For international investors, CLEO provides exposure to Indonesia's domestic consumer economy.
Indonesia has a large population and a growing middle class, creating a long-term market opportunity for packaged beverages.
Unlike highly cyclical industries such as commodities, consumer staples can provide more defensive demand characteristics.
2. Strong Brand Recognition
Cleo is an established Indonesian bottled-water brand.
Brand recognition can create an important competitive advantage because consumers often purchase packaged water based on trust, availability, taste, and perceived quality.
3. Attractive Gross Margins
CLEO's 2025 gross margin was approximately 55.9%.
Even after margin compression, that remains a relatively strong gross-profit profile.
If management can stabilize margins while increasing production volume, earnings growth could accelerate.
4. Expanding Production Network
The addition of new factories should improve the company's geographic coverage.
This could become one of the strongest long-term catalysts for CLEO.
5. Conservative Dividend Policy Supports Growth
CLEO approved a IDR 60 billion dividend for FY2025, equivalent to IDR 2.50 per share after its enlarged share count. The payout ratio was approximately 15.7% of 2025 net income.
For income investors, this is not particularly attractive.
But from a growth-investing perspective, retaining approximately 84% of earnings can be beneficial if management can reinvest that capital at attractive returns.
Cons of Investing in CLEO Stock
1. 2025 Net Income Declined
The biggest warning sign is the decline in profitability during 2025.
Revenue increased, but net income fell approximately 18%.
That means investors cannot simply assume that higher sales will automatically produce higher shareholder returns.
2. Valuation Is Not Cheap
At around IDR 374 in late July 2026, CLEO had a market capitalization of roughly IDR 9.0 trillion and a reported P/E ratio around 23x.
That valuation is not necessarily excessive for a company with double-digit growth potential.
However, it does mean investors are already paying for a meaningful portion of the company's expected future growth.
If earnings growth disappoints, the stock could experience multiple compression.
3. Low Dividend Yield
The 2026 dividend was IDR 2.50 per share.
Using a share price around IDR 374, the implied cash dividend yield is only approximately:
2.50 ÷ 374 = 0.67%
That makes CLEO much more attractive as a growth stock than as an income stock.
4. Capital Expenditure Risk
The IDR 700 billion expansion program is substantial relative to annual net income of approximately IDR 382 billion in 2025.
New factories must generate sufficient incremental revenue and cash flow to justify the investment.
If utilization rates remain low, returns on invested capital could decline.
5. Currency Risk for U.S. Investors
A U.S. investor buying CLEO is exposed to the Indonesian rupiah.
For example, an investor could earn a positive return in Indonesian rupiah but still experience a smaller return in U.S. dollars if the rupiah weakens against the dollar.
This is an important difference between investing in CLEO and investing in a U.S.-listed consumer company.
6. Emerging-Market Liquidity Risk
CLEO is considerably less liquid than major U.S. consumer stocks such as Coca-Cola, PepsiCo, or Procter & Gamble.
This can create:
Wider bid-ask spreads
Higher execution risk
Greater price volatility
More difficulty entering or exiting large positions
International investors should therefore avoid treating CLEO as equivalent to a large-cap U.S. stock.
CLEO Valuation Analysis
Using approximately IDR 374 per share as a late-July 2026 reference price and an EPS around IDR 16, CLEO traded at roughly 23x trailing earnings.
That valuation can be interpreted in two ways.
Bull Case
If CLEO successfully achieves double-digit revenue and earnings growth, a P/E around the low-to-mid 20s could be justified.
The company could benefit from:
New factory capacity
Geographic expansion
Higher sales volume
Distribution efficiency
Operating leverage
Stronger margins
Under this scenario, today's valuation could look reasonable several years from now.
Bear Case
If earnings growth remains weak and margins continue to decline, a P/E above 20x becomes difficult to justify.
A re-rating toward a lower multiple could cause the share price to fall even if the company remains profitable.
This is why earnings growth is more important than revenue growth for CLEO investors.
A Simple 2026 Earnings Scenario
Rather than predicting a single share price, investors can think about CLEO through earnings scenarios.
| Scenario | Revenue Growth | Earnings Growth | Investment View |
|---|---|---|---|
| Bear | 5% | 0–5% | Risk of valuation compression |
| Base | 10–12% | 10–15% | Reasonable long-term return potential |
| Bull | 15%+ | 18–25%+ | Strong upside potential |
These are scenario assumptions rather than company guidance or guaranteed forecasts.
The critical variable is whether the new factories create sufficient operating leverage.
CLEO vs. U.S. Bottled-Water Investments
For U.S. investors, CLEO can be viewed differently from a traditional U.S. consumer stock.
Companies such as Coca-Cola and PepsiCo provide:
Greater liquidity
U.S.-dollar reporting
Larger global scale
Longer dividend histories
More mature capital markets
CLEO offers something different:
Indonesian consumer exposure
Higher potential growth
Smaller-company characteristics
Emerging-market risk
Potential benefits from Indonesia's expanding consumption economy
Therefore, CLEO should generally be considered a satellite emerging-market investment, rather than a replacement for a diversified U.S. consumer-staples portfolio.
Is CLEO a Good Stock for Long-Term Investors?
The answer depends on the investor.
CLEO may appeal to growth investors who:
Want exposure to Indonesia
Believe packaged-water consumption will continue growing
Are comfortable with emerging-market risk
Accept lower dividend income
Have a multi-year investment horizon
Believe the new factories can generate attractive returns
CLEO may not be appropriate for investors who:
Require high dividend income
Prefer highly liquid U.S. stocks
Want U.S.-dollar assets
Are uncomfortable with currency risk
Prefer companies with decades of dividend growth
Want low valuation multiples
Final Verdict: Is CLEO Stock a Buy?
PT Sariguna Primatirta (IDX: CLEO) has a compelling long-term business story, but the stock is not obviously cheap.
The company's strongest advantages are its established Cleo brand, strong gross margins, expanding production network, exposure to Indonesia's consumer market, and relatively manageable leverage.
The biggest concerns are the 2025 decline in net income, margin pressure, significant capital expenditure requirements, relatively low dividend yield, and valuation risk.
The early 2026 numbers are encouraging because revenue grew 15.8% year over year and net income returned to positive growth. However, earnings growth of only 2.8% remained substantially below revenue growth.
For a long-term investor, the most important metrics to watch during 2026 and 2027 are:
Revenue growth
EBITDA margin
Net profit growth
Factory utilization
Free cash flow
Debt-to-EBITDA
Return on invested capital
Distribution costs
Market share
Valuation relative to earnings growth
Overall assessment: Moderately Bullish / Growth-Oriented
CLEO looks more interesting as an emerging-market growth investment than as a dividend stock. Investors who believe the company's expansion can produce sustained double-digit earnings growth may find the current valuation reasonable, while value investors may prefer to wait for a more attractive entry price.
As with any emerging-market stock, investors should also account for currency movements, liquidity, regulatory risk, and portfolio diversification.
Important Disclaimer
This article is for educational and informational purposes only and does not constitute investment advice, a recommendation to buy or sell CLEO shares, or a solicitation to invest.
International investors should independently review the company's financial statements, Indonesian Stock Exchange disclosures, applicable taxes, brokerage costs, foreign-exchange risk, and their own investment objectives before making an investment decision.
Sources and References
PT Sariguna Primatirta / Tanobel – Financial Statements
PT Sariguna Primatirta Financial StatementsPT Sariguna Primatirta – 2024 Annual Report
CLEO 2024 Annual ReportIndonesia Central Securities Depository (KSEI) – CLEO Dividend Announcement 2026
KSEI CLEO Dividend AnnouncementPT Sariguna Primatirta – Investor Relations / Information Disclosure
CLEO Information DisclosureIndo Premier / IPOT – CLEO FY2025 Financial Statements
Indo Premier / IPOT – CLEO Q1 2026 Financial Statements
IDNFinancials – CLEO Company and Market Data
IDNFinancials CLEO ProfileBareksa – CLEO 2026 Expansion and Dividend Update
About the Author
David Mulyana is the founder and editor of WorldReview1989, an independent publication dedicated to finance, investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Personal Finance
- Investing & Stock Market
- Cryptocurrency & Blockchain
- Insurance
- Banking
- Real Estate
- Business & Entrepreneurship
- Digital Marketing
- Financial Technology (FinTech)
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks.